Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12890/2020_001675 http://scihub22266oqcxt.onion/10.12890/2020_001675 32399455!7213824!32399455     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Case+Rep+Intern+Med 2020 ; 7 (5): 001675 Nephropedia Template TP {{tp|p=32399455|t=2020. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome |pdf=|usr=}}{{32399455}} gab.com Text Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome JO: Eur J Case Rep Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32399455 #FOAvip Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome. Twit Text FOAVip Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome ????Eur J Case Rep Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32399455 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32399455 #FOAvip English Wikipedia <ref>{{Cite pmid|32399455}}</ref> Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome #MMPMID32399455 van Kraaij TD; Mostard RL; Ramiro S; Magro Checa C; van Dongen CM; van Haren EH; Buijs J; Landewe RB Eur J Case Rep Intern Med 2020[]; 7 (5): 001675 PMID32399455show ga Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome. äTocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Rele(epmc).pdf DeepDyve Pubget Overpricing